Navigation Links
$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma
Date:10/18/2010

Washington, DC The National Cancer Institute has awarded a $4.37 million grant to Jeffrey A. Toretsky, MD, at Georgetown Lombardi Comprehensive Cancer Center, to advance a recent scientific laboratory discovery into a new treatment for Ewing's sarcoma. The grant, issued under the American Recovery and Reinvestment Act, will help fund preclinical toxicology studies of a new agent identified by Toretsky and his team a critical step in drug development that usually is stalled for years because of cost.

"A significant hindrance of therapeutic development is translation from the laboratory to the clinic," says Toretsky. "This funding not only allows this step to occur, but it could dramatically accelerate the time of taking our laboratory finding and turning it into a therapy for patients."

If preclinical toxicology studies are successful, a clinical trial with the agent would follow. The studies of the agent are based on a 2009 discovery in which Toretsky and his colleagues found a novel way to block the activity of the fusion protein responsible for Ewing's sarcoma, a rare cancer found in children and young adults. Toretsky described the finding in the journal Nature Medicine.

He and his colleagues discovered and successfully tested a small molecule that keeps the fusion protein from sticking to another protein that is critical for tumor formation. The researchers say this interaction is unique and is especially surprising since the Ewing's sarcoma fusion protein is extremely flexible, which allows it to change shape constantly.

"Most targeted small molecule cancer drugs inhibit the intrinsic activity of a single protein, but our agent stops two proteins from interacting. This has never been shown before with a cancer-causing fusion protein and represents a potentially novel medical therapy," says Toretsky.

Agents currently in use that work against fusion proteins inhibit a single protein to stop intrinsic enzymatic activity; one example is Gleevec, used for chronic myelogenous leukemia (CML). Torestsky believes his team's finding could provide a model upon which to design treatment for other disorders caused by the interaction between two proteins, and may be especially useful in cancers caused by translocations of genes, such as sarcomas and leukemias, the researchers say

In the United States, about 500 people are diagnosed each year with Ewing's sarcoma, and they are treated with a combination of five different chemotherapy drugs. Between 60 and 70 percent of patients survive over time, but with side effects from the treatment. Additional treatment options are available but without long-term potential for cure for patients whose cancer progresses, Toretsky says.

Discovery: A Long Journey

Torestky and his colleagues have chartered a 15-year path towards a new treatment for Ewing's sarcoma. Ewing's sarcoma is caused by the exchange of DNA between two chromosomes, a process known as a translocation. A new gene is created when the EWS gene on chromosome 22 fuses to the FLI1 gene on chromosome 11, and its product is the fusion protein EWS-FLI1 responsible for cancer formation. EWS-FLI1 is a good target for anticancer therapy since it is critical for the tumor and only present in tumor cells. It is a so-called disordered protein, which means it does not have a rigid structure. A number of cancer-causing proteins are disordered.

Previously, Toretsky and his colleagues were the first to make a recombinant EWS-FLI1 fusion protein. They used this recombinant protein to discover that the fusion protein stuck to another protein, RNA helicase A (RHA). RHA is a molecule that forms protein complexes in order to control gene transcription. "We believe that when RHA binds to EWS-FLI1, the combination becomes more powerful at turning genes on and off," says Hayriye Verda Erkizan, PhD, a postdoctoral researcher in Toretsky's lab.

Then, from a library of 3,000 small molecules loaned to Georgetown from the National Cancer Institute, the researchers searched for a small molecule that would bind on to EWS-FLI1. They found one, and further discovered the same molecule, NSC635437, could stop EWS-FLI1's fusion protein from sticking to RHA.

Erkizan described the finding as a wonderful discovery because the notion long accepted among scientists is that it is not possible to block protein-protein interactions given that the surface of many of these proteins are slippery and therefore drugs cannot bind to them.

The researchers tested the agent in laboratory cell culture, and with the help of GUMC's Drug Discovery Program, designed a stronger derivative compound they called YK-4-279. In this study, they tested YK-4-279 in two different animal models of Ewing's sarcoma and found that the agent significantly inhibited the growth of tumors. There was an 80% reduction in the growth of treated tumors compared to untreated tumors. These results serve as a proof of principle that inhibiting protein-protein interaction can work as a novel therapeutic that will target only cancer cells.

"We may be able to use this strategy to attack proteins we thought to be impervious to manipulation," he says.

Toretsky is an inventor on a patent application that has been filed by Georgetown University related to the technology described.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Anti-vomiting drug could prevent thousands of hospitalizations, save millions of dollars
2. National Institutes of Health awards $1.2 million to GSU for collaborative study on discharge decisions at hospitals
3. New report: How will the affordable care act affect 15 million uninsured young adults?
4. MJFF announces over $10 million in funding for clinical and pre-clinical PD research
5. USF and Saneron get $2.6 million to develop Alzheimers treatment using umbilical cord blood cells
6. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
7. UTHealth researchers awarded $15 million for teen pregnancy prevention
8. UC San Diego researcher awarded $3.8 million for new path to breast cancer therapy
9. WUSTL awarded $18 million to treat heart, lungs with nanotechnology
10. MSU researcher awarded $14 million to identify breast cancer risk factors
11. Type 1 diabetes research at UC San Diego gets $5 million boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... ... 24, 2017 , ... Altec Products, Inc., a leader in enterprise ... one-day technology conference in San Diego, CA. , At nVerge 2017, Altec will ... utilize and enhance their Sage ERP solutions by providing improved visibility and control to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. ... NY, who have now spent 10 years as clinical instructors for the reputable ... College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
Breaking Medicine Technology: